{"id":3257,"date":"2018-09-27T16:00:47","date_gmt":"2018-09-27T10:30:47","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=3257"},"modified":"2021-07-24T12:57:05","modified_gmt":"2021-07-24T07:27:05","slug":"the-business-cocktails-2","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktails-2","title":{"rendered":"Ceribell raises $35M; Lyra reels $29.5M; Minoryx raises Euro21M;  Alexion acquired Syntimmune"},"content":{"rendered":"<h4><strong>Ceribell raises USD 35 Million in series B round<\/strong><\/h4>\n<p><strong>Ceribell<\/strong>, Emergency EEG maker raised <strong>USD 35 million<\/strong> for commercializing its <strong>EEG system<\/strong> that can rapidly diagnose patients, who are supposed of not having convulsive seizures with no visual symptoms for the use in neurological intensive care units and emergency rooms. The Mountain View received 510(k) clearance from the <strong>FDA<\/strong> in 2017, is intended to identify patients within six minutes, compared to typical EEGs, which may take hours or days.<\/p>\n<p><strong>Lyra reels USD 29.5Million to move chronic sinusitis drug into phase 2<\/strong><\/p>\n<p><strong>Lyra Therapeutics<\/strong> is working for improving treatments of ear, nose and throat (<strong>ENT<\/strong>) diseases. The company has bagged <strong>USD29.5 million series B<\/strong> for the treatment of <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/chronic-bronchitis-market\">chronic <\/a>rhinosinusitis<\/strong> and pushed the disease into <strong>phase 2<\/strong>. <strong>LYR-210<\/strong> is based on its transmucosal drug delivery platform.<\/p>\n<p><strong>Minoryx raises Euro 21Million to expand CNS R&amp;D<\/strong><\/p>\n<p><strong>Minoryx<\/strong> of Spain has raised <strong>Euro 21.3 million in series B funding<\/strong>. <strong>Roche<\/strong> backed company extends clinical development of a <strong>neurodegenerative disease drug<\/strong>, which has fascinated the attention of organizations including <strong>Roche Venture Fund.<\/strong> The company established itself as an upcoming player in neurodegeneration R&amp;D in 2015 when it raised <strong>Euro 19.4 million series A<\/strong> round to take <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/ppar-beta-delta-agonist-pipeline-insight\">PPAR<\/a>-gamma agonist MIN-102<\/strong> into clinical trials.<\/p>\n<p><strong>Alexion<\/strong> <strong>acquired another biotech, remunerating USD 1.2Billion for Syntimmune<\/strong><\/p>\n<p><strong>Alexion<\/strong> has snapped up another biotech for <strong>USD400 million<\/strong> upfront deal for rare disease specialist Syntimmune. The acquisition gives control of <strong>SYNT001<\/strong>\u2014a neonatal Fc receptor (<strong>FcRn<\/strong>) inhibitor in <strong>phase 1b\/2a<\/strong> trials for patients with warm autoimmune hemolytic anaemia (<strong>WAIHA<\/strong>) and pemphigus vulgaris (<strong>PV<\/strong>) or pemphigus foliaceus (<strong>PF<\/strong>) to Alexion.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Ceribell raises USD 35 Million in series B round Ceribell, Emergency EEG maker raised USD 35 million for commercializing its EEG system that can rapidly diagnose patients, who are supposed of not having convulsive seizures with no visual symptoms for the use in neurological intensive care units and emergency rooms. The Mountain View received 510(k) [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":3157,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[885,1888,1892,1889,1891,1898,704,1893,1890,1894,524,1895,1897,1896],"industry":[17225],"therapeutic_areas":[17227,17245,17244,17236,17234],"class_list":["post-3257","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-alexion","tag-ceribell","tag-chronic-rhinosinusitis","tag-eeg-system","tag-ent","tag-fcrn","tag-fda","tag-lyr-210","tag-lyra-therapeutics","tag-minoryx","tag-roche","tag-roche-venture-fund","tag-synt001","tag-syntimmune","industry-pharmaceutical","therapeutic_areas-immunological-and-autoimmune-disorders","therapeutic_areas-neurology","therapeutic_areas-ophthalmology","therapeutic_areas-otolaryngology","therapeutic_areas-rare-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Ceribell raises $35M; Lyra reels $29.5M; Minoryx raises Euro21M<\/title>\n<meta name=\"description\" content=\"Ceribell, Emergency EEG maker raised USD 35 million for commercializing its EEG system that can rapidly diagnose patients,\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktails-2\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ceribell raises $35M; Lyra reels $29.5M; Minoryx raises Euro21M\" \/>\n<meta property=\"og:description\" content=\"Ceribell, Emergency EEG maker raised USD 35 million for commercializing its EEG system that can rapidly diagnose patients,\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktails-2\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2018-09-27T10:30:47+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:27:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/09\/09023959\/pharma-licensing-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"620\" \/>\n\t<meta property=\"og:image:height\" content=\"410\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Ceribell raises $35M; Lyra reels $29.5M; Minoryx raises Euro21M","description":"Ceribell, Emergency EEG maker raised USD 35 million for commercializing its EEG system that can rapidly diagnose patients,","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktails-2","og_locale":"en_US","og_type":"article","og_title":"Ceribell raises $35M; Lyra reels $29.5M; Minoryx raises Euro21M","og_description":"Ceribell, Emergency EEG maker raised USD 35 million for commercializing its EEG system that can rapidly diagnose patients,","og_url":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktails-2","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2018-09-27T10:30:47+00:00","article_modified_time":"2021-07-24T07:27:05+00:00","og_image":[{"width":620,"height":410,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/09\/09023959\/pharma-licensing-1.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktails-2","url":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktails-2","name":"Ceribell raises $35M; Lyra reels $29.5M; Minoryx raises Euro21M","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktails-2#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktails-2#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/09\/09023959\/pharma-licensing-1.jpg","datePublished":"2018-09-27T10:30:47+00:00","dateModified":"2021-07-24T07:27:05+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Ceribell, Emergency EEG maker raised USD 35 million for commercializing its EEG system that can rapidly diagnose patients,","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/the-business-cocktails-2"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktails-2#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/09\/09023959\/pharma-licensing-1.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/09\/09023959\/pharma-licensing-1.jpg","width":620,"height":410,"caption":"Johnson & Johnson"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/09\/09023959\/pharma-licensing-1-300x198.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Alexion<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Ceribell<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">chronic rhinosinusitis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">EEG system<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">ENT<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">FcRn<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">FDA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">LYR-210<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Lyra Therapeutics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Minoryx<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Roche<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Roche Venture Fund.<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">SYNT001<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Syntimmune<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Alexion<\/span>","<span class=\"advgb-post-tax-term\">Ceribell<\/span>","<span class=\"advgb-post-tax-term\">chronic rhinosinusitis<\/span>","<span class=\"advgb-post-tax-term\">EEG system<\/span>","<span class=\"advgb-post-tax-term\">ENT<\/span>","<span class=\"advgb-post-tax-term\">FcRn<\/span>","<span class=\"advgb-post-tax-term\">FDA<\/span>","<span class=\"advgb-post-tax-term\">LYR-210<\/span>","<span class=\"advgb-post-tax-term\">Lyra Therapeutics<\/span>","<span class=\"advgb-post-tax-term\">Minoryx<\/span>","<span class=\"advgb-post-tax-term\">Roche<\/span>","<span class=\"advgb-post-tax-term\">Roche Venture Fund.<\/span>","<span class=\"advgb-post-tax-term\">SYNT001<\/span>","<span class=\"advgb-post-tax-term\">Syntimmune<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 8 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Sep 27, 2018","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Sep 27, 2018 4:00 pm","modified":"Updated on Jul 24, 2021 12:57 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/3257","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=3257"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/3257\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/3157"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=3257"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=3257"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=3257"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=3257"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=3257"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}